PIVOTAL
Research type
Research Study
Full title
Pharmacological Individualisation of Voriconazole Therapy for AntifungaL treatment
IRAS ID
154228
Contact name
William Hope
Contact email
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
2013-002578-34, EudraCT
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Invasive fungal infections are a major cause of morbidity and mortality in patients with cancers of the blood and patients having stem cell transplants. This study is investigating the most effective dose of a drug called Voriconazole that is used to treat invasive fungal infections. Currently a standard dose is used which is based on the patients weight. However there are variations between individuals in how the drug is absorbed, which risks either the drug not working or the drug causing adverse events.
This study will see whether individualised dosing is effective and safe. Computer software will be used to identify the dose of Voriconazole most suitable for an individual based on their blood samples.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
14/NW/1323
Date of REC Opinion
9 Dec 2014
REC opinion
Further Information Favourable Opinion